Kojin Therapeutics
A US biotech company harnessing discoveries in cell-state and ferroptosis biology to develop treatments for cancer, and cardiovascular, immunologic, and degenerative diseases.
Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis.
Latest Kojin Therapeutics News & Features
5 January 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze